CN107868092A - 一种新型化合物及其制备方法 - Google Patents
一种新型化合物及其制备方法 Download PDFInfo
- Publication number
- CN107868092A CN107868092A CN201710868177.7A CN201710868177A CN107868092A CN 107868092 A CN107868092 A CN 107868092A CN 201710868177 A CN201710868177 A CN 201710868177A CN 107868092 A CN107868092 A CN 107868092A
- Authority
- CN
- China
- Prior art keywords
- new compound
- water
- methanol
- slug
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000000284 extract Substances 0.000 claims abstract description 31
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 238000000926 separation method Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 162
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 54
- 238000002425 crystallisation Methods 0.000 claims description 36
- 230000008025 crystallization Effects 0.000 claims description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000012452 mother liquor Substances 0.000 claims description 16
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 238000007127 saponification reaction Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000007791 liquid phase Substances 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000005660 chlorination reaction Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 241000878949 Deroceras agreste Species 0.000 claims description 3
- 241001260900 Laevicaulis alte Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 241001505912 Limax flavus Species 0.000 claims description 2
- 241001316298 Limax maximus Species 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 239000003502 gasoline Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- 238000001784 detoxification Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002557 soporific effect Effects 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241001523586 Limacidae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- -1 does It is dry Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开一种新型化合物,该新型化合物从蛞蝓中提取分离制得。本发明还公开了该新型化合物的提取分离方法,该方法简便、易操作。本发明提供的化合物,具有镇静催眠的作用,对生理性、精神性依赖脱毒或戒毒的效果显著,用于制备脱毒或戒毒药物,具有潜在的应用价值,为进一步开发蛞蝓戒毒药品提供新思路。
Description
技术领域
本发明属于生物医药化学领域,具体涉及一种新型化合物及其制备方法。
背景技术
蛞蝓,又名碾沐,为足襞蛞蝓科动物覆套足襞蛞蝓Vaginulus alte(Ferussac)的干燥全体。覆套足襞蛞(Vaginulalte(Ferussac));《广西壮药质量标准第二卷》,【性味与归经】中医咸,寒。归肺、肝、大肠经。壮医咸,寒。【功能与主治】中医祛风定惊,清热解毒,消肿止痛。用于中风僻,筋脉拘挛,惊痫,喘息,咽肿,喉痹,痈肿,丹毒,痰核,痔疮肿痛,脱肛。壮医清热毒,调气道,通龙路。用于货烟妈(咽炎)、墨病(哮喘),尊寸(脱肛),兵嘿细勒(疝气),呗农(痈疮),京瑟(闭经),蜈蚣咬伤。
现有技术对蛞蝓在抗菌、抗癌方面有广泛的研究,而目前,经过研究发现中药蛞蝓提取物有明显的镇静催眠作用,对吗啡和苯丙胺引起的小鼠兴奋性具有一定抑制作用,对吗啡依赖大鼠戒断症状具有脱毒治疗效果,且急性毒性安全,无生理和精神依赖性,若能进一步研究蛞蝓提取物中戒毒成分物质,明确其性状,这对进一步开发中药戒毒产品,具有重要的意义。
发明内容
本发明的目的是提供一种新型化合物,为研究开发中药戒毒产品提供新思路。
本发明采用以下技术方案:
一种新型化合物,其结构为
进一步的,所述新型化合物的分子式为:C3OH52O7;分子量为524;熔点:248~249℃;溶解性:白色针状或柱状结晶,不溶于水,不溶于酸、碱,易溶于甲醇、丙酮、溶于乙醇、乙酸乙酯、热三氯甲烷,微溶于冷三氯甲烷;手性C构型包括:C3,R;C6,S;C7,S;C10,S;C11,R;C12,R;C13,R;C14,R;C15,S;C18,S;C19,S;C22,R。
进一步的,所述新型化合物从蛞蝓中提取分离制得。
更进一步的,所述蛞蝓,包括覆套足襞蛞蝓(Vaginulus alte(Ferussac))、大蛞蝓(Limax maximus L.)、黄蛞蝓(L.flavus L.)、野蛞蝓(Agriolimax agrestis L.)和双线粘液蛞蝓(Phiolomycus bilineatus)中的一种或多种。
一种如上所述新型化合物的制备方法,包括以下步骤:
S1.将蛞蝓粉碎得蛞蝓粉;
S2.将蛞蝓粉投入至超临界CO2萃取器中萃取,制得萃取物;
S3.将萃取物、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热搅拌发生皂化反应,制得反应液A;
S4.将反应液A加入有机溶剂萃取,分取有机溶剂层,用水洗涤至水洗液呈中性后,分取有机溶剂层,减压回收有机溶剂,得稠膏A;
S5:在稠膏A中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
S6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun。
进一步的,以上所述新型化合物,步骤S2项下所述超临界CO2萃取的条件为:压力25KPa,温度65℃,流量400~500PV,萃取时间4h;步骤S4项下所述有机溶剂包括乙醚、乙酸乙酯和正丁醇等中的一种或两种。
一种如上所述新型化合物的制备方法,包括以下步骤:
T1.将蛞蝓粉碎得蛞蝓粉;
T2.将蛞蝓粉投入至多功能提取罐中,加入有机溶媒回流提取,过滤,提取液减压回收有机溶媒,制得稠膏B;
T3.将稠膏B、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热搅拌发生皂化反应,制得反应液B;
T4.将反应液B加入有机溶剂萃取,分取有机溶剂层,用水洗涤至水洗液呈中性后,分取有机溶剂层,减压回收有机溶剂,得稠膏C;
T5:在稠膏C中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
T6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun。
进一步的,以上所述新型化合物的制备方法中步骤T2项下所述有机溶媒包括正已烷、乙醇、甲醇、丙酮、三氯甲烷、油、汽油、石油醚、正丁醇、乙醚和乙酸乙酯等中的一种或两种。
一种如上所述新型化合物的制备方法,还包括以下步骤:取S5或T5项下母液,按甲醇:水(8:2)比例加入水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷加热使溶解、冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加入甲醇,加热溶解,冷却,析出结晶,过滤,干燥,得到所述新型化合物。
本发明的新型化合物采用简便的方法从中药蛞蝓中提取而得。所述化合物具有镇静催眠的作用,对生理性、精神性依赖脱毒或戒毒的效果显著,用于制备脱毒或戒毒药物,具有潜在的应用价值。
附图说明
1、图1为本发明新型化合物的X射线晶体结构。
2、图2为本发明新型化合物的晶体空间立体结构图。
3、图3、图4为本发明新型化合物的晶形图。
4、图5-图11为本发明新型化合物的NMR核磁共振碳(C)氢(H)谱。
5、图12-图14为本发明的新型化合物的质谱(MS)数据图。
具体实施方式
一、一种新型化合物
实施例1
本发明提供了一种新型化合物,其具体结构为:
所述化合物的具体信息如下:
(1)该化合物命名为“蛞蝓素”,其英文名为:limaxol A。
(2)化合物中的手性C构型:C3,R;C6,S;C7,S;C10,S;C11,R;C12,R;C13,R;C14,R;C15,S;C18,S;C19,S;C22,R.,其晶体结构图如图1、图2所示。
(3)其物理化学性质及光谱数据:
①分子式:C30H52O7;分子量524。
②状态:白色针(柱)状结晶(结晶溶剂:甲醇),其结晶图见图3、图4。
③熔点:248~249℃。
④溶解性:白色针(柱)状结晶,不溶于水,不溶于酸、碱,易溶于甲醇、丙酮、溶于乙醇、乙酸乙酯、三氯甲烷(热),微溶于三氯甲烷(冷)。
⑤NMR核磁共振碳(C)氢(H)谱数据如表1,NMRNMR核磁共振碳(C)氢(H)谱如图5-图11
表1
⑥质谱(MS)数据图,如图12~图14,
二、一种新型化合物的制备方法
实施例2
一种新型化合物的制备方法,包括以下步骤:
S1:取蛞蝓60kg,净选,除杂,粉碎成20目粗粉,备用;
S2:取蛞蝓粗粉,投入至超临界CO2萃取器中萃取,萃取条件为压力25PKa,温度65℃,流量400PV,萃取时间4h,得萃取物;
S3:将萃取物、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热温度至85℃,边搅拌边反应,皂化反应时间2h,得皂化反应液A;
S4:将反应液A加入乙醚萃取,分取乙醚层,用水洗涤至水洗液呈中性后,分取乙醚层,减压回收乙醚,得稠膏A;
S5:在稠膏A中,加入甲醇,加热溶解,过滤,滤液静置,析出结晶,母液备用;
S6:取结晶,通过制备型中压液相分离得到新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun;
S7:取S5项下母液,按甲醇:水(8:2)加入去离子水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷,加热使溶解,冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加入甲醇,加热溶解,冷却,静置,析出结晶,过滤,干燥,得到新型化合物。
实施例3
一种新型化合物的制备方法,包括以下步骤:
T1:将蛞蝓100kg,净选,除杂,粉碎成20目粗粉,备用;
T2:取蛞蝓粗粉,投入至多功能提取罐中,加入溶剂正已烷回流提取2次,过滤,合并提取液,减压回收正已烷,得稠膏B;
T3:将稠膏B、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热温度至95℃,边搅拌边反应,皂化反应时间3.5h,得反应液B;
T4:将反应液B加入乙酸乙酯萃取,分取乙酸乙酯液,用去离子水洗涤至水洗液呈中性后,分取乙酸乙酯液,减压回收乙酸乙酯,得稠膏C;
T5:在稠膏C中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
T6:取结晶,通过制备型中压液相分离得到新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun;
T7:取T5项下甲醇母液,按甲醇:水(8:2)加入去离子水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷加热使溶解,冷却,静析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加甲醇,加热溶解,冷却,静置,析出结晶,过滤,干燥,得到新型化合物。
实施例4
一种新型化合物的制备方法,包括以下步骤:
T1:取蛞蝓150kg,净选,除杂,粉碎成20目粗粉,备用;
T2:取蛞蝓粗粉,投入至多功能提取罐中,加入混合溶剂(三氯甲烷:丙酮=1:1)回流提取2次,过滤,合并提取液,减压回收溶剂,得稠膏B;
T3:将稠膏B、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热温度至100℃,边搅拌边反应,皂化反应时间4h,得反应液B;
T4:将反应液B加入正丁醇萃取,分取正丁醇液,用去离子水洗涤至水洗液呈中性,分取正丁醇液,减压回收正丁醇,得稠膏C;
T5:在稠膏C中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
T6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun;
T7:取T5项下母液,按甲醇:水(8:2)加入去离子水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷加热使溶解、冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加甲醇,加热溶解,冷却,静置,析出结晶,过滤,干燥,得到新型化合物。
实施例5
一种新型化合物的制备方法,包括以下步骤:
T1:取蛞蝓100kg,净选,除杂,粉碎成20目粗粉,备用;
T2:取蛞蝓粗粉,投入至多功能提取罐中,加入甲醇回流提取2次,过滤,合并提取液,减压回收甲醇,得稠膏B;
T3:将稠膏B、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热温度至90℃,边搅拌边反应,皂化反应时间3h,得反应液B;
T4:将反应液B加入混合溶剂(乙酸乙酯:乙醚=1:1)萃取,分取混合溶剂层,合并,用去离子水洗涤至水洗液呈中性,分取混合溶剂层,减压回收溶剂,得稠膏C;
T5:在稠膏C中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
T6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun;
T7:取T5项下母液,按甲醇:水(8:2)加入去离子水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷加热使溶解,冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加甲醇,加热溶解,冷却,静置,析出结晶,过滤,干燥,得到新型化合物。
实施例6
一种新型化合物的制备方法,包括以下步骤:
S1:取蛞蝓100kg,净选,除杂,粉碎成20目粗粉,备用;
S2:取蛞蝓粗粉,投入至超临界CO2萃取器中萃取,萃取条件为压力25PKa,温度65℃,流量500PV,萃取时间4h,得萃取物;
S3:将萃取物、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热温度至100℃,边搅拌边反应,皂化反应时间4h,得皂化反应液A;
S4:将反应液A加入乙酸乙酯萃取,分取乙酸乙酯层,用水洗涤至水洗液呈中性后,分取乙酸乙酯层,减压回收乙酸乙酯,得稠膏A;
S5:在稠膏A中,加入甲醇,加热溶解,过滤,滤液静置,析出结晶,母液备用;
S6:取结晶,通过制备型中压液相分离得到新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun;
S7:取S5项下母液,按甲醇:水(8:2)加入去离子水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷,加热使溶解,冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加入甲醇,加热溶解,冷却,静置,析出结晶,过滤,干燥,得到新型化合物。
Claims (11)
1.一种新型化合物,其特征在于,其结构为:
2.根据权利要求1所述新型化合物,其特征在于,所述新型化合物的分子式为:C30H52O7;分子量为524;熔点:248~249℃;溶解性:白色针状或柱状结晶,不溶于水,不溶于酸、碱,易溶于甲醇、丙酮、溶于乙醇、乙酸乙酯、热三氯甲烷,微溶于冷三氯甲烷。
3.根据权利要求1所述新型化合物,其特征在于,所述新型化合物手性C构型包括:C3,R;C6,S;C7,S;C10,S;C11,R;C12,R;C13,R;C14,R;C15,S;C18,S;C19,S;C22,R。
4.根据权利要求1所述新型化合物,其特征在于,所述新型化合物从蛞蝓中提取分离制得。
5.根据权利要求4所述新型化合物,其特征在于,所述蛞蝓,包括覆套足襞蛞蝓(Vaginulus alte(Ferussac))、大蛞蝓(Limax maximus L.)、黄蛞蝓(L.flavus L.)、野蛞蝓(Agriolimax agrestis L.)和双线粘液蛞蝓(Phiolomycus bilineatus)中的一种或多种。
6.一种如权利要求1所述新型化合物的制备方法,其特征在于,包括以下步骤:S1.将蛞蝓粉碎得蛞蝓粉;
S2.将蛞蝓粉投入至超临界CO2萃取器中萃取,制得萃取物;
S3.将萃取物、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热搅拌发生皂化反应,制得反应液A;
S4.将反应液A加入有机溶剂萃取,分取有机溶剂层,用水洗涤至水洗液呈中性后,分取有机溶剂层,减压回收有机溶剂,得稠膏A;
S5:在稠膏A中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
S6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun。
7.根据权利要求6所述新型化合物的制备方法,其特征在于,所述有机溶剂包括乙醚、乙酸乙酯和正丁醇中的一种或两种。
8.一种如权利要求1所述新型化合物的制备方法,其特征在于,包括以下步骤:
T1.将蛞蝓粉碎得蛞蝓粉;
T2.将蛞蝓粉投入至多功能提取罐中,加入有机溶媒回流提取,过滤,提取液减压回收有机溶媒,制得稠膏B;
T3.将稠膏B、氢氧化钾和水按照重量比“萃取物:氢氧化钾:水=1:1:1.5”加入反应釜中,混匀,加热搅拌发生皂化反应,制得反应液B;
T4.将反应液B加入有机溶剂萃取,分取有机溶剂层,用水洗涤至水洗液呈中性后,分取有机溶剂层,减压回收有机溶剂,得稠膏C;
T5:在稠膏C中加入甲醇,加热溶解,过滤,滤液放冷,静置,析出结晶,母液备用;
T6:取结晶,通过制备型中压液相分离得到所述新型化合物,液相条件为:反相C18柱,溶剂系统为甲醇:乙腈:异丙醇:水(70:20:6:4),流速为50ml/mun。
9.根据权利要求7所述新型化合物的制备方法,其特征在于,所述有机溶媒包括正已烷、乙醇、甲醇、丙酮、三氯甲烷、油、汽油、石油醚、正丁醇、乙醚和乙酸乙酯中的一种或两种。
10.一种如权利要求1所述新型化合物的制备方法,其特征在于,还包括以下步骤:取S5或T5项下母液,按甲醇:水(8:2)比例加入水,加热回流,析出黑色油状物,滤取甲醇溶液,回收甲醇,干燥,残渣加入三氯甲烷加热使溶解,冷却,静置析出结晶,过滤,得结晶体用少量三氯化甲烷洗涤,干燥,加入甲醇,加热溶解,冷却,析出结晶,过滤,干燥,得到所述新型化合物。
11.根据权利要求6所述新型化合物,其特征在于,所述新型化合物通过超临界CO2萃取法萃取时超临界CO2萃取的条件为:压力25KPa,温度65℃,流量400~500PV,萃取时间4h。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/115649 WO2019057220A1 (zh) | 2016-09-27 | 2018-11-15 | 一种新型化合物及其制备方法 |
US16/808,371 US10849934B2 (en) | 2016-09-27 | 2020-03-04 | Compound and preparation method thereof |
US16/917,897 US11000555B2 (en) | 2016-09-27 | 2020-06-30 | Method for preparing a limax compound and therapeutic use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016108603468 | 2016-09-27 | ||
CN201610860346 | 2016-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107868092A true CN107868092A (zh) | 2018-04-03 |
CN107868092B CN107868092B (zh) | 2021-08-10 |
Family
ID=61752478
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710868177.7A Active CN107868092B (zh) | 2016-09-27 | 2017-09-22 | 一种新型化合物及其制备方法 |
CN201710868174.3A Active CN107865890B (zh) | 2016-09-27 | 2017-09-22 | 蛞蝓提取物、提取物中有效成分提取分离方法及用途 |
CN201710867160.XA Active CN107865889B (zh) | 2016-09-27 | 2017-09-22 | 蛞蝓的新用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710868174.3A Active CN107865890B (zh) | 2016-09-27 | 2017-09-22 | 蛞蝓提取物、提取物中有效成分提取分离方法及用途 |
CN201710867160.XA Active CN107865889B (zh) | 2016-09-27 | 2017-09-22 | 蛞蝓的新用途 |
Country Status (7)
Country | Link |
---|---|
US (4) | US11116802B2 (zh) |
JP (1) | JP6767583B2 (zh) |
KR (1) | KR102185474B1 (zh) |
CN (3) | CN107868092B (zh) |
CA (2) | CA3033547C (zh) |
DE (1) | DE112017004827T5 (zh) |
WO (4) | WO2018059241A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057220A1 (zh) * | 2016-09-27 | 2019-03-28 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法 |
WO2020114096A1 (zh) * | 2018-12-05 | 2020-06-11 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法与应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113501854B (zh) * | 2021-06-02 | 2022-05-17 | 广西壮族自治区中国科学院广西植物研究所 | 一种从蛞蝓中制备胆甾醇基十七酸酯的方法 |
CN113694085A (zh) * | 2021-08-26 | 2021-11-26 | 广西医科大学 | 蛞蝓提取物在制备癌症化疗方案的联用药物中的应用 |
CN114558034A (zh) * | 2022-03-16 | 2022-05-31 | 中国中医科学院医学实验中心 | 一种蛞蝓的提取方法及其抗结直肠癌应用 |
CN115282212B (zh) * | 2022-07-22 | 2023-09-29 | 宿州亿帆药业有限公司 | 一种断金胶囊及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253297A (ja) * | 2001-02-27 | 2002-09-10 | Takeda Chem Ind Ltd | 微生物による光学活性体の製造法 |
CN1562087A (zh) * | 2004-04-15 | 2005-01-12 | 广州康采恩医药有限公司 | 治疗肺癌、慢性支气管炎和支气管哮喘的蛞蝓制剂及其制备方法 |
CN1939346A (zh) * | 2006-04-27 | 2007-04-04 | 广州康采恩医药有限公司 | 蛞蝓多糖及其生产工艺 |
CN102631371A (zh) * | 2011-02-15 | 2012-08-15 | 广州汉方现代中药研究开发有限公司 | 一种抗肺癌新药及其提取分离方法 |
CN103610699A (zh) * | 2013-12-06 | 2014-03-05 | 广州白云山汉方现代药业有限公司 | 一种蛞蝓的提取方法及其抗肺癌应用 |
CN105936894A (zh) * | 2016-06-27 | 2016-09-14 | 董晓 | 一种从蛞蝓中提取蜗牛酶的方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR898615A (fr) * | 1942-05-18 | 1945-04-27 | Ferrosan As | Procédé d'extraction d'un mélange de stérines contenant de la 7-déhydrocholestérine de mollusques |
CA2388339A1 (en) * | 1999-11-04 | 2001-05-10 | Monsanto Technology Llc | Cholesterol reducing sterol compositions, preparation and method of use |
US20070026440A1 (en) * | 2001-04-06 | 2007-02-01 | Broderick Patricia A | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry |
CN1796400B (zh) * | 2004-12-29 | 2010-06-23 | 杭州浙大力夫生物科技有限公司 | 从竹笋中提取的植物甾醇类提取物及其制备方法和用途 |
US20060204601A1 (en) * | 2005-03-09 | 2006-09-14 | Palu Afa K | Formulations and methods for preventing and treating substance abuse and addiction |
CN1846784A (zh) * | 2005-11-25 | 2006-10-18 | 广州康采恩医药有限公司 | 蛞蝓pe4糖蛋白及其生产工艺 |
CN101011417A (zh) * | 2007-02-06 | 2007-08-08 | 广州康采恩医药有限公司 | 一种治疗慢性阻塞性肺病的糖蛋白 |
US20100209542A1 (en) | 2008-11-21 | 2010-08-19 | University Of Massachusetts Medical School | Methods For Treating Withdrawal From Addictive Compounds |
US20120322781A1 (en) * | 2010-01-14 | 2012-12-20 | Umecrine Mood Ab | Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
CN102008594B (zh) * | 2010-08-17 | 2013-01-30 | 浙江省中药研究所有限公司 | 一种用于戒毒治疗的中药制剂及其制备方法 |
CN102697814A (zh) * | 2011-03-28 | 2012-10-03 | 谢金魁 | 一种治疗乙型肝炎的新药及其提取分离方法 |
CN102627682A (zh) * | 2012-03-29 | 2012-08-08 | 南昌大学 | 酯化、卤代豆甾醇衍生物及其在抗癌药物中的应用 |
CN103450310A (zh) * | 2013-08-19 | 2013-12-18 | 南昌大学 | 豆甾醇衍生物及其在制备抗癌药物中的应用 |
CN105685531A (zh) * | 2014-07-27 | 2016-06-22 | 汪永辉 | 一种蛞蝓饲料制备方法 |
CN106146596A (zh) * | 2016-07-05 | 2016-11-23 | 浙江海洋大学 | 一种铜藻β‑谷甾醇化合物及其提取方法、应用 |
JP6767583B2 (ja) * | 2016-09-27 | 2020-10-14 | グアンシー ジュフー バイオテクノロジー カンパニー リミテッド | 麻薬依存を治療する薬効のあるエキストラクト及びその調製方法 |
CN106800580B (zh) * | 2017-01-12 | 2019-05-10 | 中国药科大学 | 甾醇类衍生物及其制备方法和应用 |
CN111269241A (zh) * | 2018-12-05 | 2020-06-12 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法与应用 |
CN109646562A (zh) * | 2019-01-28 | 2019-04-19 | 谢金魁 | 一种防治copd的蛞蝓复方制剂及其制备方法 |
-
2017
- 2017-09-14 JP JP2019526360A patent/JP6767583B2/ja active Active
- 2017-09-14 DE DE112017004827.3T patent/DE112017004827T5/de active Pending
- 2017-09-14 CA CA3033547A patent/CA3033547C/en active Active
- 2017-09-14 KR KR1020197002680A patent/KR102185474B1/ko active IP Right Grant
- 2017-09-14 WO PCT/CN2017/101679 patent/WO2018059241A1/zh active Application Filing
- 2017-09-22 CN CN201710868177.7A patent/CN107868092B/zh active Active
- 2017-09-22 CN CN201710868174.3A patent/CN107865890B/zh active Active
- 2017-09-22 CN CN201710867160.XA patent/CN107865889B/zh active Active
-
2018
- 2018-11-15 WO PCT/CN2018/115651 patent/WO2019057222A1/zh active Application Filing
- 2018-11-15 WO PCT/CN2018/115649 patent/WO2019057220A1/zh active Application Filing
- 2018-11-15 WO PCT/CN2018/115650 patent/WO2019057221A1/zh active Application Filing
- 2018-11-15 CA CA3076282A patent/CA3076282C/en active Active
-
2019
- 2019-01-28 US US16/258,688 patent/US11116802B2/en active Active
-
2020
- 2020-03-04 US US16/808,371 patent/US10849934B2/en active Active
- 2020-05-25 US US16/882,741 patent/US11925665B2/en active Active
- 2020-06-30 US US16/917,897 patent/US11000555B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253297A (ja) * | 2001-02-27 | 2002-09-10 | Takeda Chem Ind Ltd | 微生物による光学活性体の製造法 |
CN1562087A (zh) * | 2004-04-15 | 2005-01-12 | 广州康采恩医药有限公司 | 治疗肺癌、慢性支气管炎和支气管哮喘的蛞蝓制剂及其制备方法 |
CN1939346A (zh) * | 2006-04-27 | 2007-04-04 | 广州康采恩医药有限公司 | 蛞蝓多糖及其生产工艺 |
CN102631371A (zh) * | 2011-02-15 | 2012-08-15 | 广州汉方现代中药研究开发有限公司 | 一种抗肺癌新药及其提取分离方法 |
CN103610699A (zh) * | 2013-12-06 | 2014-03-05 | 广州白云山汉方现代药业有限公司 | 一种蛞蝓的提取方法及其抗肺癌应用 |
CN105936894A (zh) * | 2016-06-27 | 2016-09-14 | 董晓 | 一种从蛞蝓中提取蜗牛酶的方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057220A1 (zh) * | 2016-09-27 | 2019-03-28 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法 |
WO2020114096A1 (zh) * | 2018-12-05 | 2020-06-11 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法与应用 |
CN111269241A (zh) * | 2018-12-05 | 2020-06-12 | 广西久福生物科技有限公司 | 一种新型化合物及其制备方法与应用 |
KR20210076896A (ko) * | 2018-12-05 | 2021-06-24 | 광시 지우푸 바이오테크놀로지 컴퍼니 리미티드 | 신규 화합물 및 이의 제조 방법과 응용 |
RU2758255C1 (ru) * | 2018-12-05 | 2021-10-27 | Гуанси Цзюфу Биотекнолоджи Ко., Лтд | Новое соединение, способ его получения и применение |
AU2019391065B2 (en) * | 2018-12-05 | 2021-11-18 | Guangxi Jiufu Biotechnology Co., Ltd | Novel compound, preparation method and application thereof |
JP2022501349A (ja) * | 2018-12-05 | 2022-01-06 | グアンシー ジュフー バイオテクノロジー カンパニー リミテッド | 新規化合物、その製造方法及び使用 |
JP7129121B2 (ja) | 2018-12-05 | 2022-09-01 | グアンシー ジュフー バイオテクノロジー カンパニー リミテッド | 新規化合物、その製造方法及び使用 |
KR102570122B1 (ko) | 2018-12-05 | 2023-08-23 | 광시 지우푸 바이오테크놀로지 컴퍼니 리미티드 | 신규 화합물 및 이의 제조 방법과 응용 |
US11912716B2 (en) | 2018-12-05 | 2024-02-27 | Guangxi Jiufu Biotechnology Co., Ltd | Compound, preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102185474B1 (ko) | 2020-12-03 |
CA3076282C (en) | 2022-06-14 |
US11925665B2 (en) | 2024-03-12 |
WO2019057220A1 (zh) | 2019-03-28 |
CN107865889A (zh) | 2018-04-03 |
CA3033547A1 (en) | 2018-04-05 |
US11116802B2 (en) | 2021-09-14 |
WO2019057221A1 (zh) | 2019-03-28 |
CN107865890A (zh) | 2018-04-03 |
CN107865889B (zh) | 2023-01-06 |
JP6767583B2 (ja) | 2020-10-14 |
KR20190022802A (ko) | 2019-03-06 |
CA3033547C (en) | 2021-05-18 |
JP2019523304A (ja) | 2019-08-22 |
CA3076282A1 (en) | 2019-03-28 |
WO2018059241A1 (zh) | 2018-04-05 |
CN107868092B (zh) | 2021-08-10 |
CN107865890B (zh) | 2023-01-06 |
US10849934B2 (en) | 2020-12-01 |
US20190151375A1 (en) | 2019-05-23 |
DE112017004827T5 (de) | 2019-06-06 |
US11000555B2 (en) | 2021-05-11 |
WO2019057222A1 (zh) | 2019-03-28 |
US20200330523A1 (en) | 2020-10-22 |
US20200281990A1 (en) | 2020-09-10 |
US20200199144A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107868092A (zh) | 一种新型化合物及其制备方法 | |
CN103130816A (zh) | 一种从银杏叶中制备多种活性物质的方法 | |
CN103739586A (zh) | 一种从壮药山风中提取二萜类化合物的方法 | |
CN101502610B (zh) | 超临界二氧化碳从藜芦中萃取藜芦生物碱的方法 | |
AU2019391065B2 (en) | Novel compound, preparation method and application thereof | |
CN103113218A (zh) | 一种对映贝壳杉型二萜化合物及其制备方法和应用 | |
CN104327092A (zh) | 从黄花蒿草中提取青蒿素的方法 | |
CN100494153C (zh) | 八角莽草酸提取分离技术 | |
CN105859538B (zh) | 一种甘草查尔酮a的提纯方法 | |
CN102241565A (zh) | 一种从烟草中同步提取茄尼醇和烟碱的方法 | |
CN100480257C (zh) | 从柿叶中提取活性成分熊果酸的方法 | |
CN102875559A (zh) | 一种从野花椒中提取野花椒醇碱的方法 | |
CN102241656A (zh) | 一种苜蓿素的制备方法 | |
CN110229048A (zh) | 一种亚临界流体技术提取大麻二酚及其纯化方法 | |
CN107043363B (zh) | 一种从顶花板凳果中提取东莨菪亭的方法 | |
CN101891677B (zh) | 6-甲基-2-乙基-3-羟基吡啶的生产方法 | |
CN102786472B (zh) | 利用超临界萃取-结晶技术提取分离千层塔及其毛状根中石杉碱甲的方法 | |
CN106632389B (zh) | 一种黄花蒿中提取青蒿素的方法 | |
CN113698377B (zh) | 从艳山姜叶中提取二氢醉胡椒素的方法 | |
CN105061458B (zh) | 一种无毒、高纯银杏总内酯及其单体的制备方法 | |
CN1634925B (zh) | 一种银杏内酯单体的分离纯化方法 | |
CN103146224A (zh) | 一种用新鲜红辣椒直接生产无辣味红色素的方法 | |
CN108658988A (zh) | 一种苦参碱的制备方法 | |
CN101967122A (zh) | 一种从蓖麻中提取蓖麻碱的工艺 | |
CN100451011C (zh) | 药物中间体丹参酮ⅱa提取工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |